文献速递认知障碍与谵妄老年慢病共病管理多重用药

美国养老院居民高血压治疗与降压药减停:痴呆与否及新冠前后对比

Hypertension Treatment, Blood Pressure, and Deprescribing Among US Nursing Home Residents With and Without Dementia Before and After the COVID-19 Pandemic.
PubMed 文献 · J Am Med Dir Assoc · 2025-10-10

该回顾性队列研究纳入141,630名新入住养老院且接受降压药治疗的高血压患者,评估痴呆与否及新冠前后血压管理和降压药减停情况。结果显示痴呆患者低血压患病率更高、减停降压药可能性更低(完全校正HR 0.83,95%CI 0.79-0.86),提示可能存在过度治疗。

要点

  • 痴呆患者低血压患病率高于非痴呆者,如用2类降压药时至少1次收缩压<90 mmHg者分别为16.3%与8.9%。
  • 痴呆患者接受降压药减停的可能性低于非痴呆患者,完全校正HR为0.83(95%CI 0.79-0.86)。
  • 新冠后血压监测增加,如痴呆患者从新冠前每日1.6次读数增至新冠后每日1.9次读数。

核心结论

  • 研究提示痴呆养老院居民可能存在高血压过度治疗,新冠疫情期间血压监测有所增加。
  • 结果强调可通过减停降压药来平衡血压控制与用药及监测负担。

研究设计与样本

  • 回顾性队列研究,纳入超过1100家养老院中新入住且接受降压药治疗的高血压居民,排除接受临终关怀者,N=141,630,时间范围为2018年1月2日至2022年7月3日。
  • 从入住后第14天(索引日期)起进行8周随访,测量平均血压、血压变异性和低血压/高血压患病率,按痴呆状态及新冠前后(入住时间在2020年3月11日之前 vs 当日或之后)分层。
  • 在90天随访中测量降压药减停(剂量/频率降低或停药≥7天),并使用Cox风险回归模型按痴呆状态估计风险比,校正人口学和合并症。

主要发现

  • 痴呆与非痴呆患者的血压监测相似,但新冠后监测增加,例如痴呆患者新冠前每日1.6次读数,新冠后每日1.9次读数。
  • 严重痴呆患者低血压患病率高于非痴呆患者,例如在使用2类降压药者中至少1次收缩压<90 mmHg的比例分别为16.3%与8.9%。
  • 痴呆患者发生降压药减停的可能性低于非痴呆患者,完全校正风险比为0.83(95%CI 0.79-0.86)。

关键数值与推荐

  • 降压药减停定义为剂量或频率降低或停药≥7天,随访90天。
  • 痴呆患者减停的完全校正HR为0.83(95%CI 0.79-0.86),低于非痴呆患者。
  • 使用2类降压药者中,严重痴呆患者至少1次收缩压<90 mmHg的患病率为16.3%,非痴呆患者为8.9%。

临床怎么用

  • 对痴呆养老院居民应关注低血压风险,尤其在使用多类降压药时。
  • 考虑对痴呆患者适时减停降压药,以平衡血压控制与用药及监测负担。
  • 新冠后血压监测增加,需评估监测频率的合理性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate hypertension (HTN) management and antihypertensive deprescribing among US nursing home (NH) residents with and without dementia, before and after the onset of the COVID-19 pandemic. DESIGN: Retrospective cohort study. SETTING AND PARTICIPANTS: Newly admitted NH residents with HTN treated with an antihypertensive medication who were not receiving hospice from >1100 NHs using a common electronic health record vendor (January 2, 2018-July 3, 2022) (N = 141,630). METHODS: During an 8-week follow-up period beginning on day 14 in the NH after admission (index date), we measured average blood pressure (BP), BP variability, and prevalence of hypo-/hypertension stratified by dementia status and pre- and post-COVID-19 onset (admission before vs on/after March 11, 2020). We measured antihypertensive medication deprescribing (dose/frequency decreases or cessation for ≥7 days) during a 90-day follow-up and estimated hazard ratios by dementia status using Cox hazards regression models adjusted for demographics and comorbidities. Residents were followed until their first deprescribing event or censoring (discharge, death, 90 days, or July 3, 2022). RESULTS: BP monitoring was similar between those with and without dementia, but increased post-COVID-19 (eg, 1.6 readings per day pre-COVID-19 vs 1.9 readings per day post-COVID-19 in residents with dementia). Residents with severe dementia had a higher prevalence of hypotension compared with residents without dementia (eg, 16.3% vs 8.9% with at least 1 systolic BP <90 mm Hg among those treated with 2 classes). Residents with dementia were less likely to experience deprescribing than those without dementia (fully adjusted hazard ratio, 0.83; 95% CI, 0.79-0.86). CONCLUSIONS AND IMPLICATIONS: Findings suggest potential overtreatment of HTN among residents with dementia and increased BP monitoring during the COVID-19 pandemic. Results highlight potential opportunities for deprescribing to balance BP control and medication, and monitoring burden in NH.

来源:J Am Med Dir Assoc,查看原文。版权归原作者所有。

引用

  1. Zhang S, Zullo AR, Mor V, et al. Hypertension Treatment, Blood Pressure, and Deprescribing Among US Nursing Home Residents With and Without Dementia Before and After the COVID-19 Pandemic. J Am Med Dir Assoc. 2025. PMID: 41022140. doi:10.1016/j.jamda.2025.105883

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。